Amyotrophic lateral sclerosis (ALS) has long been considered to be a purely motor disorder. However, it has become apparent that many ALS patients develop cognitive and behavioral manifestations similar to frontotemporal dementia and the term amyotrophic lateral sclerosis-frontotemporal spectrum disorder (ALS-FTSD) is now used in these circumstances. This review is intended to be an overview of the cognitive and behavioral manifestations commonly encountered in ALS patients with the goal of improving case-oriented management in clinical practice. We introduce the principal ALS-FTSD subtypes and comment on their principal clinical manifestations, neuroimaging findings, neuropathological and genetic background, and summarize available therapeutic options. Diagnostic criteria for ALS-FTSD create distinct categories based on the type of neuropsychological manifestations, i.e., changes in behavior, impaired social cognition, executive dysfunction, and language or memory impairment. Cognitive impairment is found in up to 65%, while frank dementia affects about 15% of ALS patients. ALS motor and cognitive manifestations can worsen in parallel, becoming more pronounced when bulbar functions (affecting speech, swallowing, and salivation) are involved. Dementia can precede or develop after the appearance of motor symptoms. ALS-FTSD patients have a worse prognosis and shorter survival rates than patients with ALS or frontotemporal dementia alone. Important negative prognostic factors are behavioral and personality changes. From the clinician's perspective, there are five major distinguishable ALS-FTSD subtypes: ALS with cognitive impairment, ALS with behavioral impairment, ALS with combined cognitive and behavioral impairment, fully developed frontotemporal dementia in combination with ALS, and comorbid ALS and Alzheimer's disease. Although the most consistent ALS and ALS-FTSD pathology is a disturbance in transactive response DNA binding protein 43 kDa (TDP-43) metabolism, alterations in microtubule-associated tau protein metabolism have also been observed in ALS-FTSD. Early detection and careful monitoring of cognitive deficits in ALS are crucial for patient and caregiver support and enable personalized management of individual patient needs.

Biomedical Research Institute Hasselt University 3590 Diepenbeek Belgium

Department of Neurology 3rd Faculty of Medicine Charles University and Thomayer University Hospital 140 59 Prague Czech Republic

Department of Neurology University Hospitals 3000 Leuven Belgium

Laboratory for Cognitive Neurology Department of Neurosciences Leuven Brain Institute KU 3000 Leuven Belgium

Zobrazit více v PubMed

Lomen-Hoerth C., Anderson T., Miller B. The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology. 2002;59:1077–1079. doi: 10.1212/WNL.59.7.1077. PubMed DOI

Strong M.J., Abrahams S., Goldstein L.H., Woolley S., Mclaughlin P., Snowden J., Mioshi E., Roberts-South A., Benatar M., Hortobágyi T., et al. Amyotrophic lateral sclerosis—frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria. Amyotroph. Lateral Scler. Front. Degener. 2017;18:153–174. doi: 10.1080/21678421.2016.1267768. PubMed DOI PMC

Strong M.J., Grace G.M., Freedman M., Lomen-Hoerth C., Woolley S., Goldstein L.H., Murphy J., Shoesmith C., Rosenfeld J., Leigh P.N., et al. Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 2009;10:131–146. doi: 10.1080/17482960802654364. PubMed DOI

Iazzolino B., Pain D., Peotta L., Calvo A., Moglia C., Canosa A., Manera U., Ilardi A., Bombaci A., Zucchetti J.P., et al. Validation of the revised classification of cognitive and behavioural impairment in ALS. J. Neurol. Neurosurg. Psychiatry. 2019;90:734–739. doi: 10.1136/jnnp-2018-319696. PubMed DOI

Agarwal S., Highton-Williamson E., Caga J., Matamala J.M., Dharmadasa T., Howells J., Zoing M.C., Shibuya K., Geevasinga N., Vucic S., et al. Primary lateral sclerosis and the amyotrophic lateral sclerosis–frontotemporal dementia spectrum. J. Neurol. 2018;265:1819–1828. doi: 10.1007/s00415-018-8917-5. PubMed DOI

Masrori P., Van Damme P. Amyotrophic lateral sclerosis: A clinical review. Eur. J. Neurol. 2020;27:1918–1929. doi: 10.1111/ene.14393. PubMed DOI PMC

Goldstein L.H., Abrahams S. Changes in cognition and behaviour in amyotrophic lateral sclerosis: Nature of impairment and implications for assessment. Lancet Neurol. 2013;12:368–380. doi: 10.1016/S1474-4422(13)70026-7. PubMed DOI

Chiò A., Moglia C., Canosa A., Manera U., Vasta R., Brunetti M., Barberis M., Corrado L., D’Alfonso S., Bersano E., et al. Cognitive impairment across ALS clinical stages in a population-based cohort. Neurology. 2019;93:e984–e994. doi: 10.1212/WNL.0000000000008063. PubMed DOI PMC

Vinceti G., Olney N., Mandelli M.L., Spina S., Hubbard H.I., Santos-Santos M.A., Watson C., Miller Z.A., Lomen-Hoerth C., Nichelli P., et al. Primary progressive aphasia and the FTD-MND spectrum disorders: Clinical, pathological, and neuroimaging correlates. Amyotroph. Lateral Scler. Front. Degener. 2019;20:146–158. doi: 10.1080/21678421.2018.1556695. PubMed DOI PMC

Manera U., Peotta L., Iazzolino B., Canosa A., Vasta R., Palumbo F., Torrieri M.C., Solero L., Daviddi M., Grassano M., et al. The Characteristics of Cognitive Impairment in ALS Patients Depend on the Lateralization of Motor Damage. Brain Sci. 2020;10:650. doi: 10.3390/brainsci10090650. PubMed DOI PMC

Beeldman E., Govaarts R., De Visser M., Twennaar M.K., Van Der Kooi A.J., Berg L.H.V.D., Veldink J.H., Pijnenburg Y.A.L., De Haan R.J., Schmand B.A., et al. Progression of cognitive and behavioural impairment in early amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry. 2020;91:779–780. doi: 10.1136/jnnp-2020-322992. PubMed DOI PMC

BenBrika S., Desgranges B., Eustache F., Viader F. Cognitive, Emotional and Psychological Manifestations in Amyotrophic Lateral Sclerosis at Baseline and Overtime: A Review. Front. Neurosci. 2019;13:951. doi: 10.3389/fnins.2019.00951. PubMed DOI PMC

Beeldman E., Raaphorst J., Twennaar M.K., Govaarts R., Pijnenburg Y.A.L., De Haan R.J., De Visser M., Schmand B.A. The cognitive profile of behavioural variant FTD and its similarities with ALS: A systematic review and meta-analysis. J. Neurol. Neurosurg. Psychiatry. 2018;89:995–1002. doi: 10.1136/jnnp-2017-317459. PubMed DOI

Ahmed R.M., Devenney E.M., Strikwerda-Brown C., Hodges J.R., Piguet O., Kiernan M.C. Phenotypic variability in ALS-FTD and effect on survival. Neurology. 2020;94:e2005–e2013. doi: 10.1212/WNL.0000000000009398. PubMed DOI

Christidi F., Karavasilis E., Rentzos M., Kelekis N., Evdokimidis I., Bede P. Clinical and Radiological Markers of Extra-Motor Deficits in Amyotrophic Lateral Sclerosis. Front. Neurol. 2018;9:1005. doi: 10.3389/fneur.2018.01005. PubMed DOI PMC

Abrahams S., Goldstein L.H., Al-Chalabi A., Pickering A., Morris R.G., Passingham R.E., Brooks D.J., Leigh P.N. Relation between cognitive dysfunction and pseudobulbar palsy in amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry. 1997;62:464–472. doi: 10.1136/jnnp.62.5.464. PubMed DOI PMC

Saxon J.A., Thompson J.C., Harris J.M., Richardson A.M., Langheinrich T., Rollinson S., Pickering-Brown S., Chaouch A., Ealing J., Hamdalla H., et al. Cognition and behaviour in frontotemporal dementia with and without amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry. 2020;91:1304–1311. doi: 10.1136/jnnp-2020-323969. PubMed DOI PMC

Yunusova Y., Ansari J., Ramirez J., Shellikeri S., Stanisz G.J., Black S.E., Gillingham S.M., Kiss A., Stuss N.T., Zinman L. Frontal Anatomical Correlates of Cognitive and Speech Motor Deficits in Amyotrophic Lateral Sclerosis. Behav. Neurol. 2019;2019:1–11. doi: 10.1155/2019/9518309. PubMed DOI PMC

Saxon J.A., Thompson J.C., Jones M., Harris J.M., Richardson A.M., Langheinrich T., Neary D., Mann D.M., Snowden J.S. Examining the language and behavioural profile in FTD and ALS-FTD. J. Neurol. Neurosurg. Psychiatry. 2017;88:675–680. doi: 10.1136/jnnp-2017-315667. PubMed DOI PMC

Arshad F., Paplikar A., Mekala S., Varghese F., Purushothaman V.V., Kumar D.J., Shingavi L., Vengalil S., Ramakrishnan S., Yadav R., et al. Social Cognition Deficits Are Pervasive across Both Classical and Overlap Frontotemporal Dementia Syndromes. Dement. Geriatr. Cogn. Disord. Extra. 2020;10:115–126. doi: 10.1159/000511329. PubMed DOI PMC

Duan X., Dai Q., Gong Q., Chen H. Neural mechanism of unconscious perception of surprised facial expression. NeuroImage. 2010;52:401–407. doi: 10.1016/j.neuroimage.2010.04.021. PubMed DOI

Gregory C., Lough S., Stone V., Erzinclioglu S., Martin L., Baron-Cohen S., Hodges J.R. Theory of mind in patients with frontal variant frontotemporal dementia and Alzheimer’s disease: Theoretical and practical implications. Brain. 2002;125:752–764. doi: 10.1093/brain/awf079. PubMed DOI

Olney N.T., Goodkind M.S., Lomen-Hoerth C., Whalen P.K., Williamson C.A., Holley D.E., Verstaen A., Brown L.M., Miller B.L., Kornak J., et al. Behaviour, physiology and experience of pathological laughing and crying in amyotrophic lateral sclerosis. Brain. 2011;134:3458–3469. doi: 10.1093/brain/awr297. PubMed DOI PMC

Caga J., Hsieh S., Highton-Williamson E., Zoing M.C., Ramsey E., Devenney E., Ahmed R.M., Kiernan M.C. Apathy and its impact on patient outcome in amyotrophic lateral sclerosis. J. Neurol. 2018;265:187–193. doi: 10.1007/s00415-017-8688-4. PubMed DOI

Caga J., Hsieh S., Lillo P., Dudley K., Mioshi E. The Impact of Cognitive and Behavioral Symptoms on ALS Patients and Their Caregivers. Front. Neurol. 2019;10:192. doi: 10.3389/fneur.2019.00192. PubMed DOI PMC

Long Z., Irish M., Piguet O., Kiernan M.C., Hodges J.R., Burrell J.R. Clinical and neuroimaging investigations of language disturbance in frontotemporal dementia–motor neuron disease patients. J. Neurol. 2019;266:921–933. doi: 10.1007/s00415-019-09216-0. PubMed DOI

Kamminga J., Leslie F.V., Hsieh S., Caga J., Mioshi E., Hornberger M., Ballard K.J., Kiernan M.C., Hodges J.R., Burrell J.R. Syntactic comprehension deficits across the FTD-ALS continuum. Neurobiol. Aging. 2016;41:11–18. doi: 10.1016/j.neurobiolaging.2016.02.002. PubMed DOI

Leslie F.V.C., Hsieh S., Caga J., Savage S.A., Mioshi E., Hornberger M., Kiernan M.C., Hodges J.R., Burrell J.R. Semantic deficits in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Front. Degener. 2014;16:46–53. doi: 10.3109/21678421.2014.987301. PubMed DOI

Nevler N., Ash S., McMillan C., Elman L., McCluskey L., Irwin D.J., Cho S., Liberman M., Grossman M. Automated analysis of natural speech in amyotrophic lateral sclerosis spectrum disorders. Neurology. 2020;95:e1629–e1639. doi: 10.1212/WNL.0000000000010366. PubMed DOI PMC

Quarta E., Bravi R., Scambi I., Mariotti R., Minciacchi D. Increased anxiety-like behavior and selective learning impairments are concomitant to loss of hippocampal interneurons in the presymptomatic SOD1(G93A) ALS mouse model. J. Comp. Neurol. 2015;523:1622–1638. doi: 10.1002/cne.23759. PubMed DOI

Machts J., Keute M., Kaufmann J., Schreiber S., Kasper E., Petri S., Prudlo J., Vielhaber S., Schoenfeld M.A. Longitudinal clinical and neuroanatomical correlates of memory impairment in motor neuron disease. NeuroImage Clin. 2021;29:102545. doi: 10.1016/j.nicl.2020.102545. PubMed DOI PMC

Abrahams S., Newton J., Niven E., Foley J., Bak T.H. Screening for cognition and behaviour changes in ALS. Amyotroph. Lateral Scler. Front. Degener. 2013;15:9–14. doi: 10.3109/21678421.2013.805784. PubMed DOI

Gregory J.M., McDade K., Bak T.H., Pal S., Chandran S., Smith C., Abrahams S. Executive, language and fluency dysfunction are markers of localised TDP-43 cerebral pathology in non-demented ALS. J. Neurol. Neurosurg. Psychiatry. 2020;91:149–157. doi: 10.1136/jnnp-2019-320807. PubMed DOI PMC

Woolley S.C., York M.K., Moore D.H., Strutt A.M., Murphy J., Schulz P.E., Katz J.S. Detecting frontotemporal dysfunction in ALS: Utility of the ALS Cognitive Behavioral Screen (ALS-CBS™) Amyotroph. Lateral Scler. 2009;11:303–311. doi: 10.3109/17482961003727954. PubMed DOI

Gosselt I.K., Nijboer T.C.W., Van Es M.A. An overview of screening instruments for cognition and behavior in patients with ALS: Selecting the appropriate tool for clinical practice. Amyotroph. Lateral Scler. Front. Degener. 2020;21:1–13. doi: 10.1080/21678421.2020.1732424. PubMed DOI

Rusina R., Matěj R., Cséfalvay Z., Keller J., Franková V., Vyhnálek M. Frontotemporální demence. Česká Slov. Neurol. Neurochir. 2021;84:9–29. in press.

Consonni M., Contarino V.E., Catricalà E., Bella E.D., Pensato V., Gellera C., Lauria G., Cappa S.F. Cortical markers of cognitive syndromes in amyotrophic lateral sclerosis. NeuroImage Clin. 2018;19:675–682. doi: 10.1016/j.nicl.2018.05.020. PubMed DOI PMC

Mioshi E., Lillo P., Yew B., Hsieh S., Savage S., Hodges J.R., Kiernan M.C., Hornberger M. Cortical atrophy in ALS is critically associated with neuropsychiatric and cognitive changes. Neurology. 2013;80:1117–1123. doi: 10.1212/WNL.0b013e31828869da. PubMed DOI

Omer T., Finegan E., Hutchinson S., Doherty M., Vajda A., McLaughlin R.L., Pender N., Hardiman O., Bede P. Neuroimaging patterns along the ALS-FTD spectrum: A multiparametric imaging study. Amyotroph. Lateral Scler. Front. Degener. 2017;18:611–623. doi: 10.1080/21678421.2017.1332077. PubMed DOI

Rajagopalan V., Pioro E.P. Comparing brain structural MRI and metabolic FDG-PET changes in patients with ALS-FTD: ‘the chicken or the egg?’ question. J. Neurol. Neurosurg. Psychiatry. 2014;86:952–958. doi: 10.1136/jnnp-2014-308239. PubMed DOI

Canosa A., Moglia C., Manera U., Vasta R., Torrieri M.C., Arena V., D’Ovidio F., Palumbo F., Zucchetti J.P., Iazzolino B., et al. Metabolic brain changes across different levels of cognitive impairment in ALS: A 18F-FDG-PET study. J. Neurol. Neurosurg. Psychiatry. 2021;92:357–363. doi: 10.1136/jnnp-2020-323876. PubMed DOI

Crespi C., Dodich A., Cappa S.F., Canessa N., Iannaccone S., Corbo M., Lunetta C., Falini A., Cerami C. Multimodal MRI quantification of the common neurostructural bases within the FTD-ALS continuum. Neurobiol. Aging. 2018;62:95–104. doi: 10.1016/j.neurobiolaging.2017.09.019. PubMed DOI

Castelnovo V., Canu E., Calderaro D., Riva N., Poletti B., Basaia S., Solca F., Silani V., Filippi M., Agosta F. Progression of brain functional connectivity and frontal cognitive dysfunction in ALS. NeuroImage Clin. 2020;28:102509. doi: 10.1016/j.nicl.2020.102509. PubMed DOI PMC

Häkkinen S., Chu S.A., Lee S.E. Neuroimaging in genetic frontotemporal dementia and amyotrophic lateral sclerosis. Neurobiol. Dis. 2020;145:105063. doi: 10.1016/j.nbd.2020.105063. PubMed DOI PMC

Moore K.M., Nicholas J., Grossman M., McMillan C.T., Irwin D.J., Massimo L., Van Deerlin V.M., Warren J.D., Fox N.C., Rossor M.N., et al. Age at symptom onset and death and disease duration in genetic frontotemporal dementia: An international retrospective cohort study. Lancet Neurol. 2020;19:145–156. doi: 10.1016/S1474-4422(19)30394-1. PubMed DOI PMC

Forsberg K., Graffmo K., Pakkenberg B., Weber M., Nielsen M., Marklund S., Brännström T., Andersen P.M. Misfolded SOD1 inclusions in patients with mutations in C9orf72 and other ALS/FTD-associated genes. J. Neurol. Neurosurg. Psychiatry. 2019;90:861–869. doi: 10.1136/jnnp-2018-319386. PubMed DOI PMC

Siddique N., Siddique T. Amyotrophic Lateral Sclerosis Overview. GeneReviews®. [(accessed on 30 March 2021)]; Available online: https://www.ncbi.nlm.nih.gov/books/NBK1450/

Abramzon Y.A., Fratta P., Traynor B.J., Chia R. The Overlapping Genetics of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Front. Neurosci. 2020;14:42. doi: 10.3389/fnins.2020.00042. PubMed DOI PMC

Tan R.H., Guennewig B., Dobson-Stone C., Kwok J.B., Kril J.J., Kiernan M.C., Hodges J.R., Piguet O., Halliday G.M. The underacknowledged PPA-ALS. Neurology. 2019;92:e1354–e1366. doi: 10.1212/WNL.0000000000007146. PubMed DOI

Parobková E., Rusina R., Matějčková M., Gregor V., Matěj R. Genetics of neurodegenerative dementias in ten points—What can a neurologist expect from molecular genetics? Česká Slov. Neurol. Neurochir. 2019;82:100–105. doi: 10.14735/amcsnn2019100. DOI

Geser F., Lee V.M.-Y., Trojanowski J.Q. Amyotrophic lateral sclerosis and frontotemporal lobar degeneration: A spectrum of TDP-43 proteinopathies. Neuropathology. 2010;30:103–112. doi: 10.1111/j.1440-1789.2009.01091.x. PubMed DOI PMC

Ke Y.D., Van Hummel A., Stevens C.H., Gladbach A., Ippati S., Bi M., Lee W.S., Kruger S., Van Der Hoven J., Volkerling A., et al. Short-term suppression of A315T mutant human TDP-43 expression improves functional deficits in a novel inducible transgenic mouse model of FTLD-TDP and ALS. Acta Neuropathol. 2015;130:661–678. doi: 10.1007/s00401-015-1486-0. PubMed DOI

Huang C., Zhou H., Tong J., Chen H., Liu Y.-J., Wang D., Wei X., Xia X.-G. FUS Transgenic Rats Develop the Phenotypes of Amyotrophic Lateral Sclerosis and Frontotemporal Lobar Degeneration. PLoS Genet. 2011;7:e1002011. doi: 10.1371/journal.pgen.1002011. PubMed DOI PMC

Strong M.J., Donison N.S., Volkening K. Alterations in Tau Metabolism in ALS and ALS-FTSD. Front. Neurol. 2020;11:598907. doi: 10.3389/fneur.2020.598907. PubMed DOI PMC

Harrison K.L., Hunt L.J., Ritchie C.S., Yaffe K. Dying With Dementia: Underrecognized and Stigmatized. J. Am. Geriatr. Soc. 2019;67:1548–1551. doi: 10.1111/jgs.15895. PubMed DOI PMC

Danel-Brunaud V., Touzet L., Chevalier L., Moreau C., Devos D., Vandoolaeghe S., Defebvre L., Vandolaeghe S. Ethical considerations and palliative care in patients with amyotrophic lateral sclerosis: A review. Rev. Neurol. 2017;173:300–307. doi: 10.1016/j.neurol.2017.03.032. PubMed DOI

Reinhard C., Bachoud-Lévi A.-C., Bäumer T., Bertini E., Brunelle A., Buizer A.I., Federico A., Gasser T., Groeschel S., Hermanns S., et al. The European Reference Network for Rare Neurological Diseases. Front. Neurol. 2021;11:616569. doi: 10.3389/fneur.2020.616569. PubMed DOI PMC

Molecular Pathology of ALS: What We Currently Know and What Important Information Is Still Missing